Humimic Biosystems, which formed in 2023 as a spinoff company, is focused on developing models that mimic human organs — including the heart, lungs and brain — for wide-ranging applications.
Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.